Drug & intervention
colesevelam
RxCUI 141626
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Colesevelam
Colesevelam is a bile acid sequestrant administered orally. It was developed by GelTex Pharmaceuticals and later acquired by Genzyme. It is marketed in the US by Daiichi Sankyo under the brand name Welchol and elsewhere by Genzyme as Cholestagel. In Canada, it is marketed by Valeant as Lodalis.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
11 shownThree Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibNCT05252988 · 2022-08-31
ACTIVE_NOT_RECRUITINGEffect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric BypassNCT02952963 · 2016-10-01
COMPLETEDEffects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric BypassNCT02876484 · 2016-06-01
COMPLETEDRandomized Trial Comparing Colesevelam vs. EzetimibeNCT02682680 · 2016-01-11
COMPLETEDThe Role of Metformin and Colesevelam in Human GLP-1 SecretionNCT02050074 · 2014-01-01
COMPLETEDEffect of Bile Acids on GLP-1 SecretionNCT01666223 · 2012-11-01
COMPLETEDStudy to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)NCT00990184 · 2009-09-01
COMPLETEDThe Effect of Welchol on Glucose Metabolism in Type 2 DiabeticsNCT00951899 · 2009-08-01
COMPLETEDColesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes MellitusNCT00789750 · 2009-04-01
COMPLETEDEffects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.NCT00570739 · 2007-11-01
COMPLETEDEffects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 DiabetesNCT00147745 · 2005-06-01
COMPLETEDConditions being studied
Research locations
BirminghamAlabama, United States2DallasTexas, United States2OcalaFlorida, United States2PortlandOregon, United States2San AntonioTexas, United States2San DiegoCalifornia, United States2A CoruñaSpain1BarcelonaSpain1BillingsMontana, United States1CalgaryAlberta, Canada1CharlestonSouth Carolina, United States1ChicagoIllinois, United States1
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.